AccurKardia, an innovator in ECG-based diagnostics technology, today announced that its AccurECG TM software platform has ...

Pulse Biosciences Inc (PLSE) showcases technological breakthroughs and strategic growth plans despite increased losses and ...

CHENNAI: It’s nothing but the dance of mind and machine, where neurons whisper secrets and wires weave dreams. As the digital ...

In 2024, AccurKardia received FDA Breakthrough Device Designations for two novel applications: “By pioneering these breakthrough ECG-based solutions, AccurKardia is redefining cardiac ...

Patent estate covering atrioventricular interval modulation (“AVIM”) therapy now includes 46 issued U.S. patents and 91 patents outside the U.S. that collectively comprise over 2100 claims related to ...

Additionally, recent FDA Breakthrough Device Designation was granted for AVIM therapy, focusing on patients with uncontrolled hypertension at high cardiovascular risk, which includes individuals ...

with a new product from 3i Diagnostics receiving a Breakthrough Device Designation. While the US regulator first launched the similar Breakthrough Therapy Designation for innovative medicines six ...

"Breakthrough Device" designation. This recognition, granted under the FDA’s Breakthrough Devices Program, is intended to expedite the development and review of medical technologies that offer ...

AVIM therapy was recently granted Breakthrough Device Designation by the U.S. Food and Drug Administration (“FDA”) for the treatment of uncontrolled hypertension with increased cardiovascular ...